| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6124700 | Osteoarthritis and Cartilage | 2015 | 10 Pages |
Abstract
These findings indicated that SOX9 upregulation might mediate ADAMTSs suppression at the early stage of human OA. In addition, SOX9 could be used as a potential therapeutic agent for human OA at an early stage.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Q. Zhang, Q. Ji, X. Wang, L. Kang, Y. Fu, Y. Yin, Z. Li, Y. Liu, X. Xu, Y. Wang,